Fenofibrate Intervention and Event Lowering in Diabetes.

Trial Profile

Fenofibrate Intervention and Event Lowering in Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Fenofibrate (Primary)
  • Indications Cardiovascular disorders; Coronary disorders; Diabetic complications; Diabetic retinopathy; Myocardial infarction; Stroke
  • Focus Therapeutic Use
  • Acronyms FIELD
  • Sponsors Fournier Pharma
  • Most Recent Events

    • 13 Jun 2017 Results assessing relationship between circulating fibroblast growth factor-21 levels and glycemic progression using plasma samples of patients from FIELD trial (n=9697), presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
    • 03 Oct 2015 Results published in the Diabetic Medicine.
    • 18 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top